10-Q: Stimcell Energetics Q3 2026: Net Loss Widens Amidst R&D Investment

Stimcell Energetics Inc. reported a wider net loss for the nine months ended February 28, 2026, driven by increased research and development costs for its eBalance device redesign, alongside significant related party transactions.

Summary

• Stimcell Energetics Inc. reported a net loss of $665,916 for the nine months ended February 28, 2026, a significant increase from $346,964 in the same period last year.
• Total operating expenses for the nine-month period rose by 92.1% to $617,308, primarily due to a substantial increase in research and development costs.
• The company's cash balance decreased to $10,257 as of February 28, 2026, with a working capital deficit of $1,678,420.
• The company has no revenue-generating activities and relies on financing from related parties and potential equity or debt financing to fund operations.
• A 1-for-15 reverse stock split was completed effective November 1, 2024, and the company's name was changed from Cell MedX Corp. to Stimcell Energetics Inc.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as having a negative sentiment due to the widening net loss, increasing operating expenses, significant working capital deficit, and substantial doubt about the company's ability to continue as a going concern, despite ongoing R&D efforts.

Positives

• The company is actively redesigning its eBalance microcurrent device for a more compact, affordable consumer unit with enhanced diagnostic features.
• A new study is underway with St. Boniface Hospital to explore the effects of the eBalance device on mitochondrial function, aiming to further define its physiological action.
• The company secured a new $100,000 unsecured revolving line of credit from Susan Jeffs on January 7, 2026, at a 10% annual interest rate.

Negatives

• The company reported a net loss of $665,916 for the nine months ended February 28, 2026, compared to $346,964 in the prior year.
• Operating expenses increased by 92.1% to $617,308 for the nine-month period.
• The company has a working capital deficit of $1,678,420 as of February 28, 2026.
• The company has no revenue-generating activities.
• There is substantial doubt about the company's ability to continue as a going concern within one year.
• Several related party loans are in default as of the reporting date.

Risks

• The company's continuation as a going concern is dependent on obtaining necessary financing and achieving profitable operations, which cannot be predicted with certainty.
• The company has not achieved profitable operations and has an accumulated deficit of $11,527,472.
• A significant portion of the company's liabilities is owed to related parties, some of which are in default.
• There is no assurance that related parties will continue to provide financial support.
• The company may be required to raise additional financing if it cannot generate sufficient cash flow from operations to repay outstanding debts.
• The company does not have sufficient liquidity to fund operations for the next twelve months without additional financing.

Future Outlook

Management plans to support operations and the redesign of the eBalance microcurrent device through equity or debt financing. The company expects elevated research and development expenditures to continue in the near term as development progresses.

Management Comments

• The company's continuation as a going concern is dependent upon the continued financial support of its shareholders, its ability to obtain necessary debt or equity financing to continue operations, and the attainment of profitable operations.
• The unaudited condensed consolidated interim financial statements do not give effect to any adjustments that would be necessary should the Company be unable to continue as a going concern.

Industry Context

StockSavvy.ai notes that Stimcell Energetics operates in the competitive biotech sector, focusing on therapeutic and non-therapeutic wellness products. The company's strategy to redesign its eBalance device for broader consumer accessibility and its investment in scientific studies align with industry trends towards personalized health and evidence-based wellness technologies.

Related Party Transactions

• Amounts due to related parties increased to $605,231 as of February 28, 2026, from $448,536 as of May 31, 2025.
• Notes and advances due to related parties increased to $779,992 as of February 28, 2026, from $469,874 as of May 31, 2025.
• Management fees incurred to the CEO and President totaled $67,500 for the nine months ended February 28, 2026.
• Consulting fees incurred to the CFO totaled $22,500 for the nine months ended February 28, 2026.
• Consulting fees incurred to an entity controlled by a director of the Company totaled $81,480 for the nine months ended February 28, 2026.
• Several related party loans are in default as of the date of the condensed consolidated financial statements.

Stakeholder Impact

• Shareholders face continued dilution risk due to potential future equity financing and the company's ongoing net losses.
• Creditors and lenders, particularly related parties, face risks associated with the company's going concern issues and potential defaults on loans.
• Employees may face uncertainty due to the company's financial instability and reliance on external financing.

Next Steps

• Continue redesign of the eBalance Home device into a compact, affordable consumer unit.
• Conduct study examining the effects of the eBalance microcurrent device on mitochondrial function, expected to commence in mid-April.
• Seek additional equity or debt financing to fund operations and development.

Key Dates

Recommendation

The company is in a precarious financial position with a significant going concern issue and widening losses, yet it is investing in product development and scientific research. For existing investors, holding might be considered to see if the product development and financing efforts yield positive results, but the risks are substantial. New investment is not recommended at this stage due to the high uncertainty.

Keywords

Stimcell Energetics, Form 10-Q, Quarterly Report, Biotech, Microcurrent Device, eBalance Technology, Research and Development, Related Party Transactions, Going Concern, Net Loss, SEC Filing